Summary

The body fluid analysis market is projected to grow from USD 2.62 billion in 2026 to USD 3.65 billion by 2031, growing at a CAGR of 6.9%. The increasing prevalence of neurological disorders such as Alzheimer's disease and Parkinson's disease is driving demand for cerebrospinal fluid (CSF) biomarker testing, while the growing incidence of musculoskeletal disorders and periprosthetic joint infections is expanding the use of synovial fluid analysis. Furthermore, advancements in automated analyzers, flow cytometry, immunoassays, and molecular diagnostic technologies are improving the accuracy, efficiency, and standardization of specialty body fluid testing. These innovations are enabling healthcare providers to make more informed diagnostic and treatment decisions, thereby supporting market growth. https://mnmimg.marketsandmarkets.com/Images/body-fluid-analysis-market-img-overview.webp “The clinical diagnostics segment is expected to account for the largest share of the body fluid analysis market, by application, during the forecast period.” Depending on the application, the body fluid analysis market is classified into clinical diagnostics, forensics, and research applications. The clinical diagnostics segment accounts for the largest market share due to the increasing use of body fluid analysis for the diagnosis and monitoring of neurological disorders, infections, cancers, inflammatory conditions, and reproductive health disorders. Clinical laboratories and hospitals extensively utilize technologies such as flow cytometry, immunoassays, clinical chemistry, and molecular diagnostics to analyze cerebrospinal fluid (CSF), pleural fluid, peritoneal fluid, synovial fluid, and other specialty body fluids. Additionally, the growing emphasis on early disease detection, precision diagnostics, and evidence-based clinical decision-making continues to drive demand for body fluid analysis in routine healthcare settings, making clinical diagnostics the largest and fastest-growing application segment of the market. “The clinical chemistry is likely to capture the largest share of the body fluid analysis market throughout the forecast period.” The global body fluid analysis market can be segmented by technology into microscopic examination, clinical chemistry, flow cytometry, immunoassay, polymerase chain reaction (PCR), and other technologies. Among these, the clinical chemistry segment is likely to account for the largest market share throughout the forecast period. Clinical chemistry testing remains a fundamental component of routine body fluid evaluation due to its established clinical utility, broad availability across healthcare facilities, and ability to support rapid diagnostic decision-making. Furthermore, continuous advancements in automated chemistry analyzers, increasing laboratory testing volumes, and growing demand for standardized diagnostic workflows are expected to support the continued adoption of clinical chemistry-based body fluid analysis worldwide. “Asia Pacific: The fastest-growing market for body fluid analysis testing from 2026 to 2031” The global body fluid analysis market is divided into North America, Europe, Asia Pacific, Latin America, the Middle East & Africa. Asia Pacific is projected to grow at the highest regional CAGR from 2026 to 2031. Japan has a large aging population driving demand for CSF-based neurodegenerative diagnostics. China is expanding hospital laboratory capacity through national health modernization programs. India’s network of tertiary-care hospitals and private diagnostic centers is adopting automated body fluid analysis systems. The break-up of the profile of primary participants in the body fluid analysis market: • By Company Type: Tier 1 - 40%, Tier 2 - 30%, and Tier - 30% • By Designation: C-level Executives - 27%, Directors – 18%, and Others - 55% • By Region: North America - 51%, Europe - 21%, Asia Pacific - 18%, Latin America – 6%, and Middle East & Africa - 4% Sysmex Corporation (Japan); F. Hoffmann-La Roche Ltd. (Switzerland); Danaher Corporation (US); bioMérieux SA (France); Abbott Laboratories (US); Thermo Fisher Scientific Inc. (US); QIAGEN N.V. (Netherlands); Revvity, Inc. (US); Siemens Healthineers AG (Germany); Becton, Dickinson and Company (US); HORIBA, Ltd. (Japan); Bio-Rad Laboratories, Inc. (US); and DiaSorin S.p.A. (Italy) are some of the key players in the body fluid analysis market. Research Coverage: This research report categorizes the body fluid analysis market by product (consumables and instruments), by technology (microscopic examination, clinical chemistry, flow cytometry, immunoassay, polymerase chain reaction, and other technologies), by type (collection devices and diagnostic products), by fluid type (cerebrospinal fluid, pleural fluid, peritoneal fluid, synovial fluid, semen, and pericardial fluid), by application (clinical diagnostics, forensic, and research), by end user (hospital laboratories, diagnostic laboratories, forensic laboratories, academic and research institutes, and pharmaceutical and biotechnology companies), and by region (North America, Europe, Asia Pacific, Latin America, and Middle East and Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, opportunities, and challenges influencing the growth of the body fluid analysis market. A detailed analysis of the key industry players has been done to provide insights into their business overview; solutions; key strategies such as acquisitions, agreements, and product & service launches; and recent developments associated with the body fluid analysis market. Competitive analysis of upcoming startups in the body fluid analysis market ecosystem is covered in this report. Reasons to Buy This Report: The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall body fluid analysis market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, opportunities, and challenges. The report provides insights on the following pointers: • Analysis of key drivers (growing global disease burden, increasing prevalence of reproductive health conditions and infertility, growing awareness of early disease detection), restraints (lack of standardized reimbursement structures, high cost of instruments and consumables, shortage of skilled laboratory personnel), opportunities (expansion potential across emerging economies, advancements in diagnostic technologies), and challenges (stringent and varying regulatory requirements, supply chain disruptions for reagents and kits) influencing the growth of the body fluid analysis market. • Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the body fluid analysis market. • Market Development: Comprehensive information about lucrative markets—the report analyzes the body fluid analysis market across varied regions. • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the body fluid analysis market • Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players such as Danaher (US); F. Hoffmann-La Roche Ltd. (Switzerland); Thermo Fisher Scientific Inc. (US); Becton, Dickinson and Company (US); and Abbott (US).

ページTOPに戻る

Table of Contents

1 INTRODUCTION 30
1.1 STUDY OBJECTIVES 30
1.2 MARKET DEFINITION 30
1.3 STUDY SCOPE 31
1.3.1 MARKETS COVERED AND REGIONAL SCOPE 31
1.3.2 INCLUSIONS AND EXCLUSIONS 32
1.3.3 YEARS CONSIDERED 32
1.3.4 CURRENCY CONSIDERED 32
1.4 STAKEHOLDERS 33
1.5 SUMMARY OF CHANGES 33
2 EXECUTIVE SUMMARY 35
2.1 KEY INSIGHTS AND MARKET HIGHLIGHTS 35
2.2 KEY MARKET PARTICIPANTS: SHARE INSIGHTS AND STRATEGIC DEVELOPMENTS 36
2.3 DISRUPTIVE TRENDS SHAPING THE MARKET 37
2.4 HIGH-GROWTH SEGMENTS AND EMERGING FRONTIERS 38
2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST 39
3 PREMIUM INSIGHTS 40
3.1 BODY FLUID ANALYSIS MARKET OVERVIEW 40
3.2 BODY FLUID ANALYSIS MARKET, BY PRODUCT, 2026 VS. 2031 40
3.3 BODY FLUID ANALYSIS MARKET, BY TECHNOLOGY, 2026 VS. 2031 41
3.4 BODY FLUID ANALYSIS MARKET, BY TYPE, 2026 VS. 2031 41
3.5 BODY FLUID ANALYSIS MARKET, BY FLUID TYPE, 2026 VS. 2031 42
3.6 BODY FLUID ANALYSIS MARKET, BY APPLICATION, 2026 VS. 2031 42
3.7 BODY FLUID ANALYSIS MARKET, BY END USER, 2026 VS. 2031 43
3.8 BODY FLUID ANALYSIS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 43
4 MARKET OVERVIEW 44
4.1 INTRODUCTION 44
4.2 MARKET DYNAMICS 44
4.2.1 DRIVERS 45
4.2.1.1 Growing global infectious disease, inflammatory disease, and cancer burden necessitating body fluid analysis 45
4.2.1.2 Increasing prevalence of reproductive health conditions and infertility 45
4.2.1.3 Growing awareness of early disease detection 46
4.2.2 RESTRAINTS 47
4.2.2.1 Limited and inconsistent reimbursement for advanced body
fluid testing 47
4.2.2.2 High cost of instruments and consumables 47
4.2.2.3 Shortage of skilled laboratory personnel 48
4.2.3 OPPORTUNITIES 49
4.2.3.1 Expansion potential across emerging economies 49
4.2.3.2 Advancements in diagnostic technologies 49
4.2.4 CHALLENGES 50
4.2.4.1 Stringent and varying regulatory requirements 50
4.2.4.2 Supply chain disruptions for reagents and kits 51
4.3 UNMET NEEDS AND WHITE SPACES 52
4.3.1 UNMET NEEDS IN BODY FLUID ANALYSIS MARKET 52
4.3.2 WHITE SPACE OPPORTUNITIES 53
4.4 INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES 54
4.4.1 INTERCONNECTED MARKETS 54
4.4.2 CROSS-SECTOR OPPORTUNITIES 55
4.5 STRATEGIC MOVES BY TIER 1/2/3 PLAYERS 56
4.5.1 KEY MOVES AND STRATEGIC FOCUS 56
5 INDUSTRY TRENDS 57
5.1 PORTER’S FIVE FORCES ANALYSIS 57
5.1.1 BARGAINING POWER OF SUPPLIERS 58
5.1.2 BARGAINING POWER OF BUYERS 58
5.1.3 THREAT OF NEW ENTRANTS 58
5.1.4 THREAT OF SUBSTITUTES 59
5.1.5 INTENSITY OF COMPETITIVE RIVALRY 59
5.2 MACROECONOMIC OUTLOOK 59
5.2.1 INTRODUCTION 59
5.2.2 GDP TRENDS AND FORECAST 59
5.3 SUPPLY CHAIN ANALYSIS 62
5.4 VALUE CHAIN ANALYSIS 63
5.5 ECOSYSTEM ANALYSIS 65
5.5.1 BODY FLUID ANALYSIS MARKET: ROLE OF COMPANIES IN ECOSYSTEM 65
5.6 PRICING ANALYSIS 66
5.6.1 AVERAGE SELLING PRICE OF BODY FLUID ANALYSIS PRODUCTS,
BY KEY PLAYER, 2024–2026 66
5.6.2 AVERAGE SELLING PRICE OF BODY FLUID ANALYSIS PRODUCTS, BY REGION, 2024–2026 67
5.7 TRADE ANALYSIS 68
5.7.1 IMPORT SCENARIO (HS CODE 3822) 68
5.7.2 EXPORT SCENARIO (HS CODE 3822) 69
5.8 KEY CONFERENCES & EVENTS, 2026–2027 70
5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 71
5.10 INVESTMENT & FUNDING SCENARIO 71
5.11 CASE STUDY ANALYSIS 72
5.11.1 CASE STUDY 1: IMPLEMENTATION OF AUTOMATED CSF ALZHEIMER’S BIOMARKER TESTING USING ROCHE ELECSYS ASSAYS 72
5.11.2 CASE STUDY 2: IMPLEMENTATION OF AUTOMATED BODY FLUID CELL COUNTING USING BECKMAN COLTER UNICEL DXH SERIES 73
5.11.3 CASE STUDY 3: POINT-OF-CARE TESTING FOR PLEURAL, PERITONEAL, AND CSF ANALYSIS 73
5.12 IMPACT OF US TARIFFS—BODY FLUID ANALYSIS MARKET 74
5.12.1 INTRODUCTION 74
5.12.2 KEY TARIFF RATES 74
5.12.3 PRICE IMPACT ANALYSIS 75
5.12.4 IMPACT ON COUNTRIES/REGIONS 75
5.12.4.1 North America 75
5.12.4.2 Europe 75
5.12.4.3 Asia Pacific 76
5.12.5 IMPACT ON END-USE INDUSTRIES 76
5.12.5.1 Diagnostic laboratories 76
5.12.5.2 Hospital laboratories 76
5.12.5.3 Forensic laboratories 77
5.12.5.4 Academic & research institutes 77
5.12.5.5 Pharmaceutical & biotechnology companies 77
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS 78
6.1 KEY EMERGING TECHNOLOGIES 78
6.1.1 FLOW CYTOMETRY 78
6.1.2 PCR 78
6.2 COMPLEMENTARY TECHNOLOGIES 79
6.2.1 BIOINFORMATICS & DATA ANALYTICS PLATFORMS 79
6.3 ADJACENT TECHNOLOGIES 80
6.3.1 DIGITAL PCR (DPCR) 80
6.4 TECHNOLOGY/PRODUCT ROADMAP 80
6.5 PATENT ANALYSIS 82
6.5.1 LIST OF MAJOR PATENTS 83
6.6 FUTURE APPLICATIONS 84
6.7 IMPACT OF AI/GENERATIVE AI ON BODY FLUID ANALYSIS MARKET 85
6.7.1 INTRODUCTION 85
6.7.2 TOP USE CASES AND MARKET POTENTIAL 86
6.7.3 KEY COMPANIES IMPLEMENTING AI 87
6.7.4 FUTURE OF AI 87
 
7 REGULATORY LANDSCAPE AND SUSTAINABILITY INITIATIVES 88
7.1 REGIONAL REGULATIONS AND COMPLIANCE 88
7.1.1 REGULATORY ANALYSIS 88
7.1.1.1 North America 88
7.1.1.1.1 US 88
7.1.1.1.2 Canada 88
7.1.1.2 Europe 88
7.1.1.2.1 Germany 89
7.1.1.2.2 UK 89
7.1.1.2.3 France 90
7.1.1.2.4 Italy 90
7.1.1.3 Asia Pacific 90
7.1.1.3.1 China 90
7.1.1.3.2 Japan 90
7.1.1.3.3 India 91
7.1.1.4 Latin America 91
7.1.1.4.1 Brazil 91
7.1.1.4.2 Mexico 92
7.1.1.5 Middle East 92
7.1.1.5.1 Africa 92
7.1.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 92
7.2 SUSTAINABILITY INITIATIVES 94
7.2.1 ENVIRONMENTAL IMPACT AND ECO-FRIENDLY INITIATIVES IN BODY FLUID ANALYSIS MARKET 94
7.2.1.1 Eco-friendly Initiatives 95
7.3 SUSTAINABILITY IMPACT AND REGULATORY POLICY INITIATIVES 96
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 97
8.1 DECISION-MAKING PROCESS 97
8.2 BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA 97
8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS 97
8.2.2 BUYING CRITERIA 98
8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES 99
8.4 UNMET NEEDS IN VARIOUS END-USE INDUSTRIES 100
8.5 MARKET PROFITABILITY 102
8.5.1 REVENUE POTENTIAL 102
8.5.2 COST DYNAMICS 102
8.5.3 MARGIN OPPORTUNITIES IN KEY APPLICATIONS 103
 
9 BODY FLUID ANALYSIS MARKET, BY PRODUCT 104
9.1 INTRODUCTION 105
9.2 CONSUMABLES 105
9.2.1 ONGOING INNOVATIONS IN BODY FLUID ANALYSIS TO SPUR GROWTH 105
9.3 INSTRUMENTS 109
9.3.1 TECHNOLOGICAL ADVANCEMENTS TO FOSTER MARKET GROWTH 109
10 BODY FLUID ANALYSIS MARKET, BY TECHNOLOGY 112
10.1 INTRODUCTION 113
10.2 MICROSCOPIC EXAMINATION 113
10.2.1 GROWING ADOPTION OF AUTOMATED AND DIGITAL MICROSCOPY TO DRIVE MARKET 113
10.3 CLINICAL CHEMISTRY 117
10.3.1 RISING DEMAND FOR RAPID AND ACCURATE BIOCHEMICAL ASSESSMENT FUELS ADOPTION OF CLINICAL CHEMISTRY TECHNOLOGY 117
10.4 FLOW CYTOMETRY 120
10.4.1 ADVANCEMENTS IN MULTIPARAMETRIC ANALYSIS AND AUTOMATION DRIVE THE MARKET GROWTH 120
10.5 IMMUNOASSAY 122
10.5.1 INCREASING USE OF IMMUNOASSAYS IN CANCER AND INFECTIOUS DISEASE TESTING TO AID GROWTH 122
10.6 POLYMERASE CHAIN REACTION 125
10.6.1 NEED FOR HIGH PRECISION FOR DISEASE IDENTIFICATION TO SUPPORT GROWTH 125
10.7 OTHER TECHNOLOGIES 128
11 BODY FLUID ANALYSIS MARKET, BY TYPE 131
11.1 INTRODUCTION 132
11.2 COLLECTION DEVICES 132
11.2.1 RISING DEMAND FOR ACCURATE SPECIMEN COLLECTION AND HANDLING TO PROMOTE GROWTH 132
11.3 DIAGNOSTIC PRODUCTS 135
11.3.1 TECHNOLOGICAL ADVANCEMENTS TO AUGMENT GROWTH 135
12 BODY FLUID ANALYSIS MARKET, BY FLUID TYPE 139
12.1 INTRODUCTION 140
12.2 CEREBROSPINAL FLUID 140
12.2.1 INCREASING BURDEN OF NEUROLOGICAL DISORDERS SUPPORTS MARKET GROWTH 140
12.3 PLEURAL FLUID 142
12.3.1 TECHNOLOGICAL ADVANCEMENTS IMPROVING DIAGNOSTIC ACCURACY OF PLEURAL FLUID TESTING TO DRIVE MARKET 142
 
12.4 PERITONEAL FLUID 145
12.4.1 RISING PREVALENCE OF LIVER DISORDERS AND MALIGNANT ASCITES DRIVES MARKET 145
12.5 SYNOVIAL FLUID 148
12.5.1 GROWING AWARENESS ABOUT DISEASE SURVEILLANCE, SCREENING, AND OUTBREAK RESPONSE TO DRIVE MARKET 148
12.6 SEMEN 150
12.6.1 DECLINING MALE REPRODUCTIVE HEALTH DRIVING DEMAND FOR SEMEN ANALYSIS 150
12.7 PERICARDIAL FLUID 153
12.7.1 GROWING UTILIZATION OF PERICARDIAL FLUID TESTING IN CLINICAL PRACTICES TO DRIVE MARKET 153
13 BODY FLUID ANALYSIS MARKET VOLUME ANALYSIS, BY FLUID TYPE (NUMBER OF TESTS) 156
14 BODY FLUID ANALYSIS MARKET, BY APPLICATION 157
14.1 INTRODUCTION 158
14.2 CLINICAL DIAGNOSTICS 158
14.2.1 INFECTIOUS DISEASES 161
14.2.1.1 Rising burden of infectious diseases drives adoption of body fluid analysis 161
14.2.2 INFLAMMATORY DISEASES 164
14.2.2.1 Growing burden of autoimmune and inflammatory diseases supports market growth 164
14.2.3 CANCER 167
14.2.3.1 Rising burden of cancer to fuel growth 167
14.2.4 OTHER DISEASES 169
14.3 FORENSICS 172
14.3.1 GROWING UTILIZATION OF BODY FLUID ANALYSIS IN FORENSIC AND MEDICO-LEGAL INVESTIGATIONS TO SUPPORT MARKET 172
14.4 RESEARCH 175
14.4.1 INCREASING USE OF BODY FLUID ANALYSIS IN BIOMEDICAL RESEARCH AND BIOMARKER DISCOVERY TO BOOST MARKET 175
15 BODY FLUID ANALYSIS MARKET, BY END USER 178
15.1 INTRODUCTION 179
15.2 HOSPITAL LABORATORIES 179
15.2.1 RISING HEALTHCARE INVESTMENT TO CONTRIBUTE TO GROWTH 179
15.3 DIAGNOSTIC LABORATORIES 182
15.3.1 GROWING EMPHASIS ON QUALITY CONTROL AND STANDARDIZED TESTING PROTOCOLS TO BOOST MARKET 182
15.4 FORENSIC LABORATORIES 185
15.4.1 ADVANCEMENTS IN FORENSIC TESTING AND LABORATORY INFORMATICS SUPPORT MARKET GROWTH 185
15.5 ACADEMIC & RESEARCH INSTITUTES 187
15.5.1 ADVANCEMENTS IN RESEARCH TO BOOST MARKET 187
15.6 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 190
15.6.1 INCREASING ADOPTION OF BIOMARKER-DRIVEN DRUG DEVELOPMENT TO SUPPORT MARKET GROWTH 190
16 BODY FLUID ANALYSIS MARKET, BY REGION 193
16.1 INTRODUCTION 194
16.2 NORTH AMERICA 195
16.2.1 US 200
16.2.1.1 Presence of advanced healthcare infrastructure to augment growth 200
16.2.2 CANADA 204
16.2.2.1 Favorable government initiatives to fuel market 204
16.3 EUROPE 208
16.3.1 GERMANY 211
16.3.1.1 Increasing healthcare expenditure to advance growth 211
16.3.2 UK 216
16.3.2.1 Growing number of diagnostic centers to fuel market 216
16.3.3 FRANCE 219
16.3.3.1 Increasing demand for early disease diagnosis to augment growth 219
16.3.4 ITALY 223
16.3.4.1 Growing adoption of advanced diagnostic technologies to fuel market 223
16.3.5 SPAIN 226
16.3.5.1 Increased government initiatives to boost market 226
16.3.6 REST OF EUROPE 229
16.4 ASIA PACIFIC 233
16.4.1 CHINA 237
16.4.1.1 Rising public access to modern healthcare to spur growth 237
16.4.2 JAPAN 240
16.4.2.1 Universal healthcare reimbursement policy to foster growth 240
16.4.3 INDIA 243
16.4.3.1 Increased government investments for healthcare sector to bolster growth 243
16.4.4 REST OF ASIA PACIFIC 247
16.5 LATIN AMERICA 252
16.5.1 RISING DISEASE INCIDENCE AND HEALTHCARE INFRASTRUCTURAL IMPROVEMENTS TO DRIVE MARKET 252
16.6 MIDDLE EAST & AFRICA 256
16.6.1 BOOMING HEALTHCARE INVESTMENTS TO AID GROWTH 256
 
17 COMPETITIVE LANDSCAPE 260
17.1 INTRODUCTION 260
17.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 260
17.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN BODY FLUID ANALYSIS MARKET 260
17.3 REVENUE ANALYSIS, 2023–2025 262
17.4 MARKET SHARE ANALYSIS, 2025 263
17.4.1 GLOBAL MARKET SHARE ANALYSIS, 2025 263
17.4.2 US MARKET SHARE ANALYSIS, 2025 265
17.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 265
17.5.1 STARS 265
17.5.2 EMERGING LEADERS 265
17.5.3 PERVASIVE PLAYERS 266
17.5.4 PARTICIPANTS 266
17.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025 267
17.5.5.1 Company footprint 267
17.5.5.2 Region footprint 267
17.5.5.3 Product footprint 268
17.5.5.4 Type footprint 269
17.5.5.5 Application footprint 269
17.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 270
17.6.1 PROGRESSIVE COMPANIES 270
17.6.2 RESPONSIVE COMPANIES 270
17.6.3 DYNAMIC COMPANIES 270
17.6.4 STARTING BLOCKS 270
17.6.5 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 272
17.6.5.1 Detailed list of key startups/SMEs 272
17.6.5.2 Competitive benchmarking of startups/SMEs 272
17.7 COMPANY VALUATION & FINANCIAL METRICS 273
17.7.1 FINANCIAL METRICS 273
17.7.2 COMPANY VALUATION 274
17.8 PRODUCT COMPARISON 274
17.9 COMPETITIVE SCENARIO 275
17.9.1 PRODUCT LAUNCHES & APPROVALS 275
17.9.2 DEALS 276
17.9.3 EXPANSIONS 277
 
18 COMPANY PROFILES 278
18.1 KEY PLAYERS 278
18.1.1 DANAHER 278
18.1.1.1 Business overview 278
18.1.1.2 Products offered 279
18.1.1.3 Recent developments 281
18.1.1.3.1 Deals 281
18.1.1.4 MnM view 281
18.1.1.4.1 Key strengths 281
18.1.1.4.2 Strategic choices 282
18.1.1.4.3 Weaknesses and competitive threats 282
18.1.2 F. HOFFMANN-LA ROCHE LTD 283
18.1.2.1 Business overview 283
18.1.2.2 Products offered 284
18.1.2.3 Recent developments 286
18.1.2.3.1 Product launches & approvals 286
18.1.2.4 MnM view 286
18.1.2.4.1 Key strengths 286
18.1.2.4.2 Strategic choices 286
18.1.2.4.3 Weaknesses and competitive threats 287
18.1.3 BECTON, DICKINSON AND COMPANY (BD) 288
18.1.3.1 Business overview 288
18.1.3.2 Products offered 289
18.1.3.3 MnM view 291
18.1.3.3.1 Key strengths 291
18.1.3.3.2 Strategic choices 291
18.1.3.3.3 Weaknesses and competitive threats 291
18.1.4 ABBOTT 292
18.1.4.1 Business overview 292
18.1.4.2 Products offered 293
18.1.4.3 MnM view 294
18.1.4.3.1 Key strengths 294
18.1.4.3.2 Strategic choices 294
18.1.4.3.3 Weaknesses & competitive threats 294
18.1.5 THERMO FISHER SCIENTIFIC INC. 295
18.1.5.1 Business overview 295
18.1.5.2 Products offered 296
18.1.5.3 Recent developments 298
18.1.5.3.1 Expansions 298
18.1.5.4 MnM view 298
18.1.5.4.1 Key strengths 298
18.1.5.4.2 Strategic choices 298
18.1.5.4.3 Weaknesses and competitive threats 298
18.1.6 SIEMENS HEALTHINEERS AG 299
18.1.6.1 Business overview 299
18.1.6.2 Products offered 300
18.1.6.3 Recent developments 302
18.1.6.3.1 Deals 302
18.1.6.3.2 Expansions 302
18.1.7 BIOMÉRIEUX 303
18.1.7.1 Business overview 303
18.1.7.2 Products offered 305
18.1.8 SYSMEX CORPORATION 306
18.1.8.1 Business overview 306
18.1.8.2 Products offered 307
18.1.8.3 Recent developments 308
18.1.8.3.1 Deals 308
18.1.9 BIO-RAD LABORATORIES 309
18.1.9.1 Business overview 309
18.1.9.2 Products offered 310
18.1.10 QIAGEN 312
18.1.10.1 Business overview 312
18.1.10.2 Products offered 313
18.1.10.3 Recent developments 314
18.1.10.3.1 Product launches and approvals 314
18.1.11 REVVITY 315
18.1.11.1 Business overview 315
18.1.11.2 Products offered 317
18.1.12 DIASORIN S.P.A. 318
18.1.12.1 Business overview 318
18.1.12.2 Products offered 319
18.1.13 HORIBA, LTD. 321
18.1.13.1 Business overview 321
18.1.13.2 Products offered 323
18.2 OTHER PLAYERS 324
18.2.1 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD. 324
18.2.2 VIRCELL S.L. 325
18.2.3 FUJIREBIO 326
18.2.4 ERBA GROUP 327
18.2.5 GUANGZHOU WONDFO BIOTECH CO., LTD. 328
18.2.6 MESO SCALE DIAGNOSTICS, LLC 329
18.2.7 RANDOX LABORATORIES LTD. 330
18.2.8 AMPRION DIAGNOSTICS 331
18.2.9 ATILA BIOSYSTEMS 332
18.2.10 QUANTERIX 333
18.2.11 ALAMAR BIOSCIENCES 334
18.2.12 GENEPROOF 335
19 RESEARCH METHODOLOGY 336
19.1 RESEARCH DATA 336
19.1.1 SECONDARY DATA 337
19.1.1.1 List of secondary sources 337
19.1.1.2 Key data from secondary sources 338
19.1.2 PRIMARY DATA 338
19.1.2.1 List of primary sources 339
19.1.2.2 Key data from primary sources 339
19.1.2.3 Key industry insights 340
19.1.2.4 Breakdown of primary interviews 341
19.2 MARKET SIZE ESTIMATION 341
19.2.1 TOTAL MARKET SIZE: BODY FLUID ANALYSIS MARKET 341
19.2.2 BOTTOM-UP APPROACH 341
19.2.2.1 Approach 1: Revenue estimation of key players 342
19.2.2.2 Approach 2: Study of annual reports and investor presentations 342
19.2.2.3 Approach 3: Primary interviews 342
19.2.2.4 Growth forecast 343
19.2.2.5 CAGR projections 343
19.2.3 TOP-DOWN APPROACH 344
19.3 DATA TRIANGULATION 345
19.4 RESEARCH ASSUMPTIONS 345
19.4.1 STUDY-RELATED ASSUMPTIONS 345
19.5 STUDY ASSUMPTIONS 346
19.5.1 PARAMETRIC ASSUMPTIONS 346
19.5.2 GROWTH RATE ASSUMPTIONS 347
19.6 RESEARCH LIMITATIONS 347
19.7 RISK ASSESSMENT 347
20 APPENDIX 348
20.1 DISCUSSION GUIDE 348
20.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 352
20.3 CUSTOMIZATION OPTIONS 354
20.4 RELATED REPORTS 354
20.5 AUTHOR DETAILS 355

ページTOPに戻る

List of Tables/Graphs

TABLE 1 BODY FLUID ANALYSIS MARKET: PORTER’S FIVE FORCES ANALYSIS 58
TABLE 2 GDP PERCENTAGE CHANGE (%), BY KEY COUNTRY, 2023–2030 59
TABLE 3 NORTH AMERICA: MACROECONOMIC INDICATORS 61
TABLE 4 NORTH AMERICA: COUNTRY-WISE MACROECONOMIC INDICATORS 61
TABLE 5 EUROPE: MACROECONOMIC INDICATORS 61
TABLE 6 ASIA PACIFIC: MACROECONOMIC INDICATORS 61
TABLE 7 LATIN AMERICA: MACROECONOMIC INDICATORS 62
TABLE 8 MIDDLE EAST & AFRICA: MACROECONOMIC INDICATORS 62
TABLE 9 AVERAGE SELLING PRICE OF BODY FLUID ANALYSIS PRODUCTS, BY KEY PLAYER, 2024–2026 (USD) 67
TABLE 10 AVERAGE SELLING PRICE OF BODY FLUID ANALYSIS PRODUCTS, BY REGION, 2024–2026 (USD) 67
TABLE 11 IMPORT DATA FOR HS CODE 3822-COMPLIANT PRODUCTS, BY COUNTRY,
2021–2025 (USD MILLION) 68
TABLE 12 EXPORT DATA FOR HS CODE 3822-COMPLIANT PRODUCTS, BY COUNTRY,
2021–2025 (USD MILLION) 69
TABLE 13 BODY FLUID ANALYSIS MARKET: KEY CONFERENCES AND EVENTS, 2026–2027 70
TABLE 14 US-ADJUSTED RECIPROCAL TARIFF RATES 74
TABLE 15 KEY PATENTS IN BODY FLUID ANALYSIS MARKET, 2022–2026 83
TABLE 16 KEY COMPANIES IMPLEMENTING AI IN BODY FLUID ANALYSIS MARKET 87
TABLE 17 CLASSIFICATION OF IVD DEVICES IN EUROPE 89
TABLE 18 TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS IN JAPAN 91
TABLE 19 NORTH AMERICA: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 92
TABLE 20 EUROPE: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 93
TABLE 21 ASIA PACIFIC: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 93
TABLE 22 LATIN AMERICA: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 94
TABLE 23 REST OF THE WORLD: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 94
TABLE 24 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT (%) 98
TABLE 25 KEY BUYING CRITERIA, BY PRODUCT 98
TABLE 26 ADOPTION BARRIERS & INTERNAL CHALLENGES 99
TABLE 27 BODY FLUID ANALYSIS MARKET: UNMET NEEDS IN VARIOUS END-USE INDUSTRIES 101
TABLE 28 BODY FLUID ANALYSIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 105
TABLE 29 CONSUMABLES OFFERED BY KEY PLAYERS 106
TABLE 30 BODY FLUID ANALYSIS CONSUMABLES MARKET, BY REGION,
2024–2031 (USD MILLION) 107
TABLE 31 NORTH AMERICA: BODY FLUID ANALYSIS CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 107
TABLE 32 EUROPE: BODY FLUID ANALYSIS CONSUMABLES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 108
TABLE 33 ASIA PACIFIC: BODY FLUID ANALYSIS CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 108
TABLE 34 TESTING INSTRUMENTS OFFERED BY KEY PLAYERS 109
TABLE 35 BODY FLUID ANALYSIS INSTRUMENTS MARKET, BY REGION,
2024–2031 (USD MILLION) 110
TABLE 36 NORTH AMERICA: BODY FLUID ANALYSIS INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 110
TABLE 37 EUROPE: BODY FLUID ANALYSIS INSTRUMENTS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 111
TABLE 38 ASIA PACIFIC: BODY FLUID ANALYSIS INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 111
TABLE 39 BODY FLUID ANALYSIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 113
TABLE 40 MICROSCOPIC EXAMINATION-BASED TESTS AND DEVICES OFFERED
BY KEY PLAYERS 114
TABLE 41 BODY FLUID ANALYSIS MARKET FOR MICROSCOPIC EXAMINATION, BY REGION, 2024–2031 (USD MILLION) 115
TABLE 42 NORTH AMERICA: BODY FLUID ANALYSIS MARKET FOR MICROSCOPIC EXAMINATION, BY COUNTRY, 2024–2031 (USD MILLION) 115
TABLE 43 EUROPE: BODY FLUID ANALYSIS MARKET FOR MICROSCOPIC EXAMINATION,
BY COUNTRY, 2024–2031 (USD MILLION) 116
TABLE 44 ASIA PACIFIC: BODY FLUID ANALYSIS MARKET FOR MICROSCOPIC EXAMINATION, BY COUNTRY, 2024–2031 (USD MILLION) 116
TABLE 45 CLINICAL CHEMISTRY TECHNOLOGY-BASED TESTS AND DEVICES OFFERED
BY KEY PLAYERS 117
TABLE 46 BODY FLUID ANALYSIS MARKET FOR CLINICAL CHEMISTRY, BY REGION,
2024–2031 (USD MILLION) 118
TABLE 47 NORTH AMERICA: BODY FLUID ANALYSIS MARKET FOR CLINICAL CHEMISTRY,
BY COUNTRY, 2024–2031 (USD MILLION) 118
TABLE 48 EUROPE: BODY FLUID ANALYSIS MARKET FOR CLINICAL CHEMISTRY, BY COUNTRY, 2024–2031 (USD MILLION) 119
TABLE 49 ASIA PACIFIC: BODY FLUID ANALYSIS MARKET FOR CLINICAL CHEMISTRY,
BY COUNTRY, 2024–2031 (USD MILLION) 119
TABLE 50 BODY FLUID ANALYSIS MARKET FOR FLOW CYTOMETRY, BY REGION,
2024–2031 (USD MILLION) 120
TABLE 51 NORTH AMERICA: BODY FLUID ANALYSIS MARKET FOR FLOW CYTOMETRY,
BY COUNTRY, 2024–2031 (USD MILLION) 121
TABLE 52 EUROPE: BODY FLUID ANALYSIS MARKET FOR FLOW CYTOMETRY, BY COUNTRY, 2024–2031 (USD MILLION) 121
TABLE 53 ASIA PACIFIC: BODY FLUID ANALYSIS MARKET FOR FLOW CYTOMETRY,
BY COUNTRY, 2024–2031 (USD MILLION) 122
TABLE 54 IMMUNOASSAY PRODUCTS OFFERED BY KEY PLAYERS 123
TABLE 55 BODY FLUID ANALYSIS MARKET FOR IMMUNOASSAY, BY REGION,
2024–2031 (USD MILLION) 123
TABLE 56 NORTH AMERICA: BODY FLUID ANALYSIS MARKET FOR IMMUNOASSAY,
BY COUNTRY, 2024–2031 (USD MILLION) 124
TABLE 57 EUROPE: BODY FLUID ANALYSIS MARKET FOR IMMUNOASSAY, BY COUNTRY, 2024–2031 (USD MILLION) 124
TABLE 58 ASIA PACIFIC: BODY FLUID ANALYSIS MARKET FOR IMMUNOASSAY, BY COUNTRY, 2024–2031 (USD MILLION) 125
TABLE 59 PCR-BASED TESTS AND DEVICES OFFERED BY KEY PLAYERS 126
TABLE 60 BODY FLUID ANALYSIS MARKET FOR PCR, BY REGION, 2024–2031 (USD MILLION) 126
TABLE 61 NORTH AMERICA: BODY FLUID ANALYSIS MARKET FOR PCR, BY COUNTRY,
2024–2031 (USD MILLION) 127
TABLE 62 EUROPE: BODY FLUID ANALYSIS MARKET FOR PCR, BY COUNTRY,
2024–2031 (USD MILLION) 127
TABLE 63 ASIA PACIFIC: BODY FLUID ANALYSIS MARKET FOR PCR, BY COUNTRY,
2024–2031 (USD MILLION) 128
TABLE 64 BODY FLUID ANALYSIS MARKET FOR OTHER TECHNOLOGIES, BY REGION,
2024–2031 (USD MILLION) 129
TABLE 65 NORTH AMERICA: BODY FLUID ANALYSIS MARKET FOR OTHER TECHNOLOGIES,
BY COUNTRY, 2024–2031 (USD MILLION) 129
TABLE 66 EUROPE: BODY FLUID ANALYSIS MARKET FOR OTHER TECHNOLOGIES,
BY COUNTRY, 2024–2031 (USD MILLION) 130
TABLE 67 ASIA PACIFIC: BODY FLUID ANALYSIS MARKET FOR OTHER TECHNOLOGIES,
BY COUNTRY, 2024–2031 (USD MILLION) 130
TABLE 68 BODY FLUID ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 132
TABLE 69 BODY FLUID ANALYSIS MARKET FOR COLLECTION DEVICES, BY REGION,
2024–2031 (USD MILLION) 133
TABLE 70 NORTH AMERICA: BODY FLUID ANALYSIS MARKET FOR COLLECTION DEVICES,
BY COUNTRY, 2024–2031 (USD MILLION) 133
TABLE 71 EUROPE: BODY FLUID ANALYSIS MARKET FOR COLLECTION DEVICES,
BY COUNTRY, 2024–2031 (USD MILLION) 134
TABLE 72 ASIA PACIFIC: BODY FLUID ANALYSIS MARKET FOR COLLECTION DEVICES,
BY COUNTRY, 2024–2031 (USD MILLION) 134
TABLE 73 DIAGNOSTIC PRODUCTS OFFERED BY KEY PLAYERS 135
TABLE 74 BODY FLUID ANALYSIS MARKET FOR DIAGNOSTIC PRODUCTS, BY REGION,
2024–2031 (USD MILLION) 136
TABLE 75 NORTH AMERICA: BODY FLUID ANALYSIS MARKET FOR DIAGNOSTIC PRODUCTS, BY COUNTRY, 2024–2031 (USD MILLION) 137
TABLE 76 EUROPE: BODY FLUID ANALYSIS MARKET FOR DIAGNOSTIC PRODUCTS,
BY COUNTRY, 2024–2031 (USD MILLION) 137
TABLE 77 ASIA PACIFIC: BODY FLUID ANALYSIS MARKET FOR DIAGNOSTIC PRODUCTS,
BY COUNTRY, 2024–2031 (USD MILLION) 138
TABLE 78 BODY FLUID ANALYSIS MARKET, BY FLUID TYPE, 2024–2031 (USD MILLION) 140
TABLE 79 BODY FLUID ANALYSIS MARKET FOR CSF, BY REGION, 2024–2031 (USD MILLION) 141
TABLE 80 NORTH AMERICA: BODY FLUID ANALYSIS MARKET FOR CSF, BY COUNTRY,
2024–2031 (USD MILLION) 141
TABLE 81 EUROPE: BODY FLUID ANALYSIS MARKET FOR CSF, BY COUNTRY,
2024–2031 (USD MILLION) 142
TABLE 82 ASIA PACIFIC: BODY FLUID ANALYSIS MARKET FOR CSF, BY COUNTRY,
2024–2031 (USD MILLION) 142
TABLE 83 BODY FLUID ANALYSIS MARKET FOR PLEURAL FLUID, BY REGION,
2024–2031 (USD MILLION) 143
TABLE 84 NORTH AMERICA: BODY FLUID ANALYSIS MARKET FOR PLEURAL FLUID,
BY COUNTRY, 2024–2031 (USD MILLION) 144
TABLE 85 EUROPE: BODY FLUID ANALYSIS MARKET FOR PLEURAL FLUID, BY COUNTRY, 2024–2031 (USD MILLION) 144
TABLE 86 ASIA PACIFIC: BODY FLUID ANALYSIS MARKET FOR PLEURAL FLUID, BY COUNTRY, 2024–2031 (USD MILLION) 145
TABLE 87 BODY FLUID ANALYSIS MARKET FOR PERITONEAL FLUID, BY REGION,
2024–2031 (USD MILLION) 146
TABLE 88 NORTH AMERICA: BODY FLUID ANALYSIS MARKET FOR PERITONEAL FLUID,
BY COUNTRY, 2024–2031 (USD MILLION) 146
TABLE 89 EUROPE: BODY FLUID ANALYSIS MARKET FOR PERITONEAL FLUID, BY COUNTRY, 2024–2031 (USD MILLION) 147
TABLE 90 ASIA PACIFIC: BODY FLUID ANALYSIS MARKET FOR PERITONEAL FLUID,
BY COUNTRY, 2024–2031 (USD MILLION) 147
TABLE 91 BODY FLUID ANALYSIS MARKET FOR SYNOVIAL FLUID, BY REGION,
2024–2031 (USD MILLION) 148
TABLE 92 NORTH AMERICA: BODY FLUID ANALYSIS MARKET FOR SYNOVIAL FLUID,
BY COUNTRY, 2024–2031 (USD MILLION) 149
TABLE 93 EUROPE: BODY FLUID ANALYSIS MARKET FOR SYNOVIAL FLUID, BY COUNTRY, 2024–2031 (USD MILLION) 149
TABLE 94 ASIA PACIFIC: BODY FLUID ANALYSIS MARKET FOR SYNOVIAL FLUID, BY COUNTRY, 2024–2031 (USD MILLION) 150
TABLE 95 BODY FLUID ANALYSIS MARKET FOR SEMEN, BY REGION,
2024–2031 (USD MILLION) 151
TABLE 96 NORTH AMERICA: BODY FLUID ANALYSIS MARKET FOR SEMEN, BY COUNTRY, 2024–2031 (USD MILLION) 151
TABLE 97 EUROPE: BODY FLUID ANALYSIS MARKET FOR SEMEN, BY COUNTRY,
2024–2031 (USD MILLION) 152
TABLE 98 ASIA PACIFIC: BODY FLUID ANALYSIS MARKET FOR SEMEN, BY COUNTRY,
2024–2031 (USD MILLION) 152
TABLE 99 BODY FLUID ANALYSIS MARKET FOR PERICARDIAL FLUID, BY REGION,
2024–2031 (USD MILLION) 153
TABLE 100 NORTH AMERICA: BODY FLUID ANALYSIS MARKET FOR PERICARDIAL FLUID,
BY COUNTRY, 2024–2031 (USD MILLION) 154
TABLE 101 EUROPE: BODY FLUID ANALYSIS MARKET FOR PERICARDIAL FLUID, BY COUNTRY, 2024–2031 (USD MILLION) 154
TABLE 102 ASIA PACIFIC: BODY FLUID ANALYSIS MARKET FOR PERICARDIAL FLUID,
BY COUNTRY, 2024–2031 (USD MILLION) 155
TABLE 103 BODY FLUID ANALYSIS MARKET, BY FLUID TYPE, 2024–2031 (IN THOUSANDS) 156
TABLE 104 BODY FLUID ANALYSIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 158
TABLE 105 BODY FLUID ANALYSIS MARKET FOR CLINICAL DIAGNOSTICS, BY TYPE,
2024–2031 (USD MILLION) 159
TABLE 106 BODY FLUID ANALYSIS MARKET FOR CLINICAL DIAGNOSTICS, BY REGION,
2024–2031 (USD MILLION) 159
TABLE 107 NORTH AMERICA: BODY FLUID ANALYSIS MARKET FOR CLINICAL DIAGNOSTICS,
BY COUNTRY, 2024–2031 (USD MILLION) 160
TABLE 108 EUROPE: BODY FLUID ANALYSIS MARKET FOR CLINICAL DIAGNOSTICS,
BY COUNTRY, 2024–2031 (USD MILLION) 160
TABLE 109 ASIA PACIFIC: BODY FLUID ANALYSIS MARKET FOR CLINICAL DIAGNOSTICS,
BY COUNTRY, 2024–2031 (USD MILLION) 161
TABLE 110 INFECTIOUS DISEASE PRODUCTS OFFERED BY KEY PLAYERS 162
TABLE 111 BODY FLUID ANALYSIS MARKET FOR INFECTIOUS DISEASES, BY REGION,
2024–2031 (USD MILLION) 162
TABLE 112 NORTH AMERICA: BODY FLUID ANALYSIS MARKET FOR INFECTIOUS DISEASES,
BY COUNTRY, 2024–2031 (USD MILLION) 163
TABLE 113 EUROPE: BODY FLUID ANALYSIS MARKET FOR INFECTIOUS DISEASES,
BY COUNTRY, 2024–2031 (USD MILLION) 163
TABLE 114 ASIA PACIFIC: BODY FLUID ANALYSIS MARKET FOR INFECTIOUS DISEASES,
BY COUNTRY, 2024–2031 (USD MILLION) 164
TABLE 115 TUBERCULOSIS TESTING PRODUCTS OFFERED BY KEY PLAYERS 165
TABLE 116 BODY FLUID ANALYSIS MARKET FOR INFLAMMATORY DISEASES, BY REGION, 2024–2031 (USD MILLION) 165
TABLE 117 NORTH AMERICA: BODY FLUID ANALYSIS MARKET FOR INFLAMMATORY DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 166
TABLE 118 EUROPE: BODY FLUID ANALYSIS MARKET FOR INFLAMMATORY DISEASES,
BY COUNTRY, 2024–2031 (USD MILLION) 166
TABLE 119 ASIA PACIFIC: BODY FLUID ANALYSIS MARKET FOR INFLAMMATORY DISEASES,
BY COUNTRY, 2024–2031 (USD MILLION) 167
TABLE 120 INCREASING INCIDENCE OF CANCER, BY REGION, 2022 VS 2040 167
TABLE 121 BODY FLUID ANALYSIS MARKET FOR CANCER, BY REGION,
2024–2031 (USD MILLION) 168
TABLE 122 NORTH AMERICA: BODY FLUID ANALYSIS MARKET FOR CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 168
TABLE 123 EUROPE: BODY FLUID ANALYSIS MARKET FOR CANCER, BY COUNTRY,
2024–2031 (USD MILLION) 169
TABLE 124 ASIA PACIFIC: BODY FLUID ANALYSIS MARKET FOR CANCER, BY COUNTRY,
2024–2031 (USD MILLION) 169
TABLE 125 BODY FLUID ANALYSIS MARKET FOR OTHER DISEASES, BY REGION,
2024–2031 (USD MILLION) 170
TABLE 126 NORTH AMERICA: BODY FLUID ANALYSIS MARKET FOR OTHER DISEASES,
BY COUNTRY, 2024–2031 (USD MILLION) 171
TABLE 127 EUROPE: BODY FLUID ANALYSIS MARKET FOR OTHER DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 171
TABLE 128 ASIA PACIFIC: BODY FLUID ANALYSIS MARKET FOR OTHER DISEASES,
BY COUNTRY, 2024–2031 (USD MILLION) 172
TABLE 129 BODY FLUID ANALYSIS MARKET FOR FORENSICS, BY REGION,
2024–2031 (USD MILLION) 173
TABLE 130 NORTH AMERICA: BODY FLUID ANALYSIS MARKET FOR FORENSICS, BY COUNTRY, 2024–2031 (USD MILLION) 173
TABLE 131 EUROPE: BODY FLUID ANALYSIS MARKET FOR FORENSICS, BY COUNTRY,
2024–2031 (USD MILLION) 174
TABLE 132 ASIA PACIFIC: BODY FLUID ANALYSIS MARKET FOR FORENSICS, BY COUNTRY, 2024–2031 (USD MILLION) 174
TABLE 133 BODY FLUID ANALYSIS MARKET FOR RESEARCH, BY REGION,
2024–2031 (USD MILLION) 175
TABLE 134 NORTH AMERICA: BODY FLUID ANALYSIS MARKET FOR RESEARCH, BY COUNTRY, 2024–2031 (USD MILLION) 176
TABLE 135 EUROPE: BODY FLUID ANALYSIS MARKET FOR RESEARCH, BY COUNTRY,
2024–2031 (USD MILLION) 176
TABLE 136 ASIA PACIFIC: BODY FLUID ANALYSIS MARKET FOR RESEARCH, BY COUNTRY, 2024–2031 (USD MILLION) 177
TABLE 137 BODY FLUID ANALYSIS MARKET, BY END USER, 2024–2031 (USD MILLION) 179
TABLE 138 BODY FLUID ANALYSIS MARKET FOR HOSPITAL LABORATORIES, BY REGION, 2024–2031 (USD MILLION) 180
TABLE 139 NORTH AMERICA: BODY FLUID ANALYSIS MARKET FOR HOSPITAL LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 181
TABLE 140 EUROPE: BODY FLUID ANALYSIS MARKET FOR HOSPITAL LABORATORIES,
BY COUNTRY, 2024–2031 (USD MILLION) 181
TABLE 141 ASIA PACIFIC: BODY FLUID ANALYSIS MARKET FOR HOSPITAL LABORATORIES,
BY COUNTRY, 2024–2031 (USD MILLION) 182
TABLE 142 BODY FLUID ANALYSIS MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2024–2031 (USD MILLION) 183
TABLE 143 NORTH AMERICA: BODY FLUID ANALYSIS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 183
TABLE 144 EUROPE: BODY FLUID ANALYSIS MARKET FOR DIAGNOSTIC LABORATORIES,
BY COUNTRY, 2024–2031 (USD MILLION) 184
TABLE 145 ASIA PACIFIC: BODY FLUID ANALYSIS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 184
TABLE 146 BODY FLUID ANALYSIS MARKET FOR FORENSIC LABORATORIES, BY REGION, 2024–2031 (USD MILLION) 185
TABLE 147 NORTH AMERICA: BODY FLUID ANALYSIS MARKET FOR FORENSIC LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 186
TABLE 148 EUROPE: BODY FLUID ANALYSIS MARKET FOR FORENSIC LABORATORIES,
BY COUNTRY, 2024–2031 (USD MILLION) 186
TABLE 149 ASIA PACIFIC: BODY FLUID ANALYSIS MARKET FOR FORENSIC LABORATORIES,
BY COUNTRY, 2024–2031 (USD MILLION) 187
TABLE 150 BODY FLUID ANALYSIS MARKET FOR ACADEMIC & RESEARCH INSTITUTES,
BY REGION, 2024–2031 (USD MILLION) 188
TABLE 151 NORTH AMERICA: BODY FLUID ANALYSIS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 188
TABLE 152 EUROPE: BODY FLUID ANALYSIS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 189
TABLE 153 ASIA PACIFIC: BODY FLUID ANALYSIS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 189
TABLE 154 BODY FLUID ANALYSIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024–2031 (USD MILLION) 190
TABLE 155 NORTH AMERICA: BODY FLUID ANALYSIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 191
TABLE 156 EUROPE: BODY FLUID ANALYSIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 191
TABLE 157 ASIA PACIFIC: BODY FLUID ANALYSIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 192
TABLE 158 BODY FLUID ANALYSIS MARKET, BY REGION, 2024–2031 (USD MILLION) 194
TABLE 159 NORTH AMERICA: BODY FLUID ANALYSIS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 196
TABLE 160 NORTH AMERICA: BODY FLUID ANALYSIS MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 197
TABLE 161 NORTH AMERICA: BODY FLUID ANALYSIS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 197
TABLE 162 NORTH AMERICA: BODY FLUID ANALYSIS MARKET, BY TYPE,
2024–2031 (USD MILLION) 197
TABLE 163 NORTH AMERICA: BODY FLUID ANALYSIS MARKET, BY FLUID TYPE,
2024–2031 (USD MILLION) 198
TABLE 164 NORTH AMERICA: BODY FLUID ANALYSIS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 198
TABLE 165 NORTH AMERICA: BODY FLUID ANALYSIS MARKET FOR CLINICAL DIAGNOSTICS,
BY TYPE, 2024–2031 (USD MILLION) 199
TABLE 166 NORTH AMERICA: BODY FLUID ANALYSIS MARKET, BY END USER,
2024–2031 (USD MILLION) 199
TABLE 167 US: BODY FLUID ANALYSIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 200
TABLE 168 US: BODY FLUID ANALYSIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 201
TABLE 169 US: BODY FLUID ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 201
TABLE 170 US: BODY FLUID ANALYSIS MARKET, BY FLUID TYPE, 2024–2031 (USD MILLION) 202
TABLE 171 US: BODY FLUID ANALYSIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 202
TABLE 172 US: BODY FLUID ANALYSIS MARKET FOR CLINICAL DIAGNOSTICS, BY TYPE,
2024–2031 (USD MILLION) 203
TABLE 173 US: BODY FLUID ANALYSIS MARKET, BY END USER, 2024–2031 (USD MILLION) 203
TABLE 174 CANADA: BODY FLUID ANALYSIS MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 204
TABLE 175 CANADA: BODY FLUID ANALYSIS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 205
TABLE 176 CANADA: BODY FLUID ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 205
TABLE 177 CANADA: BODY FLUID ANALYSIS MARKET, BY FLUID TYPE,
2024–2031 (USD MILLION) 206
TABLE 178 CANADA: BODY FLUID ANALYSIS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 206
TABLE 179 CANADA: BODY FLUID ANALYSIS MARKET FOR CLINICAL DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION) 207
TABLE 180 CANADA: BODY FLUID ANALYSIS MARKET, BY END USER,
2024–2031 (USD MILLION) 207
TABLE 181 EUROPE: BODY FLUID ANALYSIS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 208
TABLE 182 EUROPE: BODY FLUID ANALYSIS MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 209
TABLE 183 EUROPE: BODY FLUID ANALYSIS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 209
TABLE 184 EUROPE: BODY FLUID ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 209
TABLE 185 EUROPE: BODY FLUID ANALYSIS MARKET, BY FLUID TYPE,
2024–2031 (USD MILLION) 210
TABLE 186 EUROPE: BODY FLUID ANALYSIS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 210
TABLE 187 EUROPE: BODY FLUID ANALYSIS MARKET FOR CLINICAL DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION) 211
TABLE 188 EUROPE: BODY FLUID ANALYSIS MARKET, BY END USER,
2024–2031 (USD MILLION) 211
TABLE 189 GERMANY: BODY FLUID ANALYSIS MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 212
TABLE 190 GERMANY: BODY FLUID ANALYSIS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 213
TABLE 191 GERMANY: BODY FLUID ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 213
TABLE 192 GERMANY: BODY FLUID ANALYSIS MARKET, BY FLUID TYPE,
2024–2031 (USD MILLION) 214
TABLE 193 GERMANY: BODY FLUID ANALYSIS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 214
TABLE 194 GERMANY: BODY FLUID ANALYSIS MARKET FOR CLINICAL DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION) 215
TABLE 195 GERMANY: BODY FLUID ANALYSIS MARKET, BY END USER,
2024–2031 (USD MILLION) 215
TABLE 196 UK: BODY FLUID ANALYSIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 217
TABLE 197 UK: BODY FLUID ANALYSIS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 217
TABLE 198 UK: BODY FLUID ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 217
TABLE 199 UK: BODY FLUID ANALYSIS MARKET, BY FLUID TYPE, 2024–2031 (USD MILLION) 218
TABLE 200 UK: BODY FLUID ANALYSIS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 218
TABLE 201 UK: BODY FLUID ANALYSIS MARKET FOR CLINICAL DIAGNOSTICS, BY TYPE,
2024–2031 (USD MILLION) 219
TABLE 202 UK: BODY FLUID ANALYSIS MARKET, BY END USER, 2024–2031 (USD MILLION) 219
TABLE 203 FRANCE: BODY FLUID ANALYSIS MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 220
TABLE 204 FRANCE: BODY FLUID ANALYSIS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 220
TABLE 205 FRANCE: BODY FLUID ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 221
TABLE 206 FRANCE: BODY FLUID ANALYSIS MARKET, BY FLUID TYPE,
2024–2031 (USD MILLION) 221
TABLE 207 FRANCE: BODY FLUID ANALYSIS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 221
TABLE 208 FRANCE: BODY FLUID ANALYSIS MARKET FOR CLINICAL DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION) 222
TABLE 209 FRANCE: BODY FLUID ANALYSIS MARKET, BY END USER,
2024–2031 (USD MILLION) 222
TABLE 210 ITALY: BODY FLUID ANALYSIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 223
TABLE 211 ITALY: BODY FLUID ANALYSIS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 224
TABLE 212 ITALY: BODY FLUID ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 224
TABLE 213 ITALY: BODY FLUID ANALYSIS MARKET, BY FLUID TYPE,
2024–2031 (USD MILLION) 225
TABLE 214 ITALY: BODY FLUID ANALYSIS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 225
TABLE 215 ITALY: BODY FLUID ANALYSIS MARKET FOR CLINICAL DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION) 226
TABLE 216 ITALY: BODY FLUID ANALYSIS MARKET, BY END USER, 2024–2031 (USD MILLION) 226
TABLE 217 SPAIN: BODY FLUID ANALYSIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 227
TABLE 218 SPAIN: BODY FLUID ANALYSIS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 227
TABLE 219 SPAIN: BODY FLUID ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 228
TABLE 220 SPAIN: BODY FLUID ANALYSIS MARKET, BY FLUID TYPE,
2024–2031 (USD MILLION) 228
TABLE 221 SPAIN: BODY FLUID ANALYSIS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 228
TABLE 222 SPAIN: BODY FLUID ANALYSIS MARKET FOR CLINICAL DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION) 229
TABLE 223 SPAIN: BODY FLUID ANALYSIS MARKET, BY END USER, 2024–2031 (USD MILLION) 229
TABLE 224 REST OF EUROPE: BODY FLUID ANALYSIS MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 230
TABLE 225 REST OF EUROPE: BODY FLUID ANALYSIS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 230
TABLE 226 REST OF EUROPE: BODY FLUID ANALYSIS MARKET, BY TYPE,
2024–2031 (USD MILLION) 231
TABLE 227 REST OF EUROPE: BODY FLUID ANALYSIS MARKET, BY FLUID TYPE,
2024–2031 (USD MILLION) 231
TABLE 228 REST OF EUROPE: BODY FLUID ANALYSIS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 231
TABLE 229 REST OF EUROPE: BODY FLUID ANALYSIS MARKET FOR CLINICAL DIAGNOSTICS,
BY TYPE, 2024–2031 (USD MILLION) 232
TABLE 230 REST OF EUROPE: BODY FLUID ANALYSIS MARKET, BY END USER,
2024–2031 (USD MILLION) 232
TABLE 231 ASIA PACIFIC: BODY FLUID ANALYSIS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 234
TABLE 232 ASIA PACIFIC: BODY FLUID ANALYSIS MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 235
TABLE 233 ASIA PACIFIC: BODY FLUID ANALYSIS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 235
TABLE 234 ASIA PACIFIC: BODY FLUID ANALYSIS MARKET, BY TYPE,
2024–2031 (USD MILLION) 235
TABLE 235 ASIA PACIFIC: BODY FLUID ANALYSIS MARKET, BY FLUID TYPE,
2024–2031 (USD MILLION) 236
TABLE 236 ASIA PACIFIC: BODY FLUID ANALYSIS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 236
TABLE 237 ASIA PACIFIC: BODY FLUID ANALYSIS MARKET FOR CLINICAL DIAGNOSTICS,
BY TYPE, 2024–2031 (USD MILLION) 237
TABLE 238 ASIA PACIFIC: BODY FLUID ANALYSIS MARKET, BY END USER,
2024–2031 (USD MILLION) 237
TABLE 239 CHINA: BODY FLUID ANALYSIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 238
TABLE 240 CHINA: BODY FLUID ANALYSIS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 238
TABLE 241 CHINA: BODY FLUID ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 239
TABLE 242 CHINA: BODY FLUID ANALYSIS MARKET, BY FLUID TYPE,
2024–2031 (USD MILLION) 239
TABLE 243 CHINA: BODY FLUID ANALYSIS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 239
TABLE 244 CHINA: BODY FLUID ANALYSIS MARKET FOR CLINICAL DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION) 240
TABLE 245 CHINA: BODY FLUID ANALYSIS MARKET, BY END USER,
2024–2031 (USD MILLION) 240
TABLE 246 JAPAN: BODY FLUID ANALYSIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 241
TABLE 247 JAPAN: BODY FLUID ANALYSIS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 241
TABLE 248 JAPAN: BODY FLUID ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 242
TABLE 249 JAPAN: BODY FLUID ANALYSIS MARKET, BY FLUID TYPE,
2024–2031 (USD MILLION) 242
TABLE 250 JAPAN: BODY FLUID ANALYSIS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 242
TABLE 251 JAPAN: BODY FLUID ANALYSIS MARKET FOR CLINICAL DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION) 243
TABLE 252 JAPAN: BODY FLUID ANALYSIS MARKET, BY END USER,
2024–2031 (USD MILLION) 243
TABLE 253 INDIA: BODY FLUID ANALYSIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 244
TABLE 254 INDIA: BODY FLUID ANALYSIS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 245
TABLE 255 INDIA: BODY FLUID ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 245
TABLE 256 INDIA: BODY FLUID ANALYSIS MARKET, BY FLUID TYPE,
2024–2031 (USD MILLION) 246
TABLE 257 INDIA: BODY FLUID ANALYSIS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 246
TABLE 258 INDIA: BODY FLUID ANALYSIS MARKET FOR CLINICAL DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION) 247
TABLE 259 INDIA: BODY FLUID ANALYSIS MARKET, BY END USER, 2024–2031 (USD MILLION) 247
TABLE 260 REST OF ASIA PACIFIC: BODY FLUID ANALYSIS MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 248
TABLE 261 REST OF ASIA PACIFIC: BODY FLUID ANALYSIS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 249
TABLE 262 REST OF ASIA PACIFIC: BODY FLUID ANALYSIS MARKET, BY TYPE,
2024–2031 (USD MILLION) 249
TABLE 263 REST OF ASIA PACIFIC: BODY FLUID ANALYSIS MARKET, BY FLUID TYPE,
2024–2031 (USD MILLION) 250
TABLE 264 REST OF ASIA PACIFIC: BODY FLUID ANALYSIS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 250
TABLE 265 REST OF ASIA PACIFIC: BODY FLUID ANALYSIS MARKET FOR CLINICAL DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION) 251
TABLE 266 REST OF ASIA PACIFIC: BODY FLUID ANALYSIS MARKET, BY END USER,
2024–2031 (USD MILLION) 251
TABLE 267 LATIN AMERICA: BODY FLUID ANALYSIS MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 253
TABLE 268 LATIN AMERICA: BODY FLUID ANALYSIS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 253
TABLE 269 LATIN AMERICA: BODY FLUID ANALYSIS MARKET, BY TYPE,
2024–2031 (USD MILLION) 254
TABLE 270 LATIN AMERICA: BODY FLUID ANALYSIS MARKET, BY FLUID TYPE,
2024–2031 (USD MILLION) 254
TABLE 271 LATIN AMERICA: BODY FLUID ANALYSIS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 254
TABLE 272 LATIN AMERICA: BODY FLUID ANALYSIS MARKET FOR CLINICAL DIAGNOSTICS,
BY TYPE, 2024–2031 (USD MILLION) 255
TABLE 273 LATIN AMERICA: BODY FLUID ANALYSIS MARKET, BY END USER,
2024–2031 (USD MILLION) 255
TABLE 274 MIDDLE EAST & AFRICA: BODY FLUID ANALYSIS MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 256
TABLE 275 MIDDLE EAST & AFRICA: BODY FLUID ANALYSIS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 257
TABLE 276 MIDDLE EAST & AFRICA: BODY FLUID ANALYSIS MARKET, BY TYPE,
2024–2031 (USD MILLION) 257
TABLE 277 MIDDLE EAST & AFRICA: BODY FLUID ANALYSIS MARKET, BY FLUID TYPE,
2024–2031 (USD MILLION) 258
TABLE 278 MIDDLE EAST & AFRICA: BODY FLUID ANALYSIS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 258
TABLE 279 MIDDLE EAST & AFRICA: BODY FLUID ANALYSIS MARKET FOR CLINICAL DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION) 259
TABLE 280 MIDDLE EAST & AFRICA: BODY FLUID ANALYSIS MARKET, BY END USER,
2024–2031 (USD MILLION) 259
TABLE 281 OVERVIEW OF STRATEGIES DEPLOYED BY KEY COMPANIES IN
BODY FLUID ANALYSIS MARKET, JANUARY 2023-JUNE 2026 260
TABLE 282 BODY FLUID ANALYSIS MARKET: DEGREE OF COMPETITION 263
TABLE 283 BODY FLUID ANALYSIS MARKET: REGION FOOTPRINT 267
TABLE 284 BODY FLUID ANALYSIS MARKET: PRODUCT FOOTPRINT 268
TABLE 285 BODY FLUID ANALYSIS MARKET: TYPE FOOTPRINT 269
TABLE 286 BODY FLUID ANALYSIS MARKET: APPLICATION FOOTPRINT 269
TABLE 287 BODY FLUID ANALYSIS MARKET: DETAILED LIST OF KEY STARTUPS/SMES 272
TABLE 288 BODY FLUID ANALYSIS MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES (1/2) 272
TABLE 289 BODY FLUID ANALYSIS MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES (2/2) 273
TABLE 290 BODY FLUID ANALYSIS MARKET: PRODUCT LAUNCHES & APPROVALS,
JANUARY 2023–JUNE 2026 275
TABLE 291 BODY FLUID ANALYSIS MARKET: DEALS, JANUARY 2023–JUNE 2026 276
TABLE 292 BODY FLUID ANALYSIS: EXPANSIONS, JANUARY 2023–JUNE 2026 277
TABLE 293 DANAHER: COMPANY OVERVIEW 278
TABLE 294 DANAHER: PRODUCTS OFFERED 279
TABLE 295 DANAHER: DEALS, JANUARY 2023–JUNE 2026 281
TABLE 296 F. HOFFMANN-LA ROCHE LTD: COMPANY OVERVIEW 283
TABLE 297 F. HOFFMANN-LA ROCHE LTD: PRODUCTS OFFERED 284
TABLE 298 F. HOFFMANN-LA ROCHE LTD: PRODUCT LAUNCHES & APPROVALS,
JANUARY 2023–APRIL 2026 286
TABLE 299 BECTON, DICKINSON AND COMPANY (BD): COMPANY OVERVIEW 288
TABLE 300 BECTON, DICKINSON AND COMPANY (BD): PRODUCTS OFFERED 289
TABLE 301 ABBOTT: COMPANY OVERVIEW 292
TABLE 302 ABBOTT: PRODUCTS OFFERED 293
TABLE 303 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW 295
TABLE 304 THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED 296
TABLE 305 THERMO FISHER SCIENTIFIC INC.: EXPANSIONS, JANUARY 2023–APRIL 2026 298
TABLE 306 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW 299
TABLE 307 SIEMENS HEALTHINEERS AG: PRODUCTS OFFERED 300
TABLE 308 SIEMENS HEALTHINEERS AG: DEALS, JANUARY 2023–APRIL 2026 302
TABLE 309 SIEMENS HEALTHINEERS AG: EXPANSIONS, JANUARY 2023–APRIL 2026 302
TABLE 310 BIOMÉRIEUX: COMPANY OVERVIEW 303
TABLE 311 BIOMÉRIEUX: PRODUCTS OFFERED 305
TABLE 312 SYSMEX: COMPANY OVERVIEW 306
TABLE 313 SYSMEX CORPORATION: PRODUCTS OFFERED 307
TABLE 314 SYSMEX CORPORATION: DEALS, JANUARY 2023–APRIL 2026 308
TABLE 315 BIO-RAD LABORATORIES: COMPANY OVERVIEW 309
TABLE 316 BIO-RAD LABORATORIES: PRODUCTS OFFERED 310
TABLE 317 QIAGEN: COMPANY OVERVIEW 312
TABLE 318 QIAGEN: PRODUCTS OFFERED 313
TABLE 319 QIAGEN: PRODUCT LAUNCHES AND APPROVALS,
JANUARY 2021–DECEMBER 2024 314
TABLE 320 REVVITY: COMPANY OVERVIEW 315
TABLE 321 REVVITY: PRODUCTS OFFERED 317
TABLE 322 DIASORIN S.P.A.: COMPANY OVERVIEW 318
TABLE 323 DIASORIN S.P.A.: PRODUCTS OFFERED 319
TABLE 324 HORIBA, LTD.: COMPANY OVERVIEW 321
TABLE 325 HORIBA LTD.: PRODUCTS OFFERED 323
TABLE 326 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.: COMPANY OVERVIEW 324
TABLE 327 VIRCELL S.L.: COMPANY OVERVIEW 325
TABLE 328 FUJIREBIO: COMPANY OVERVIEW 326
TABLE 329 ERBA GROUP: COMPANY OVERVIEW 327
TABLE 330 GUANGZHOU WONDFO BIOTECH CO., LTD.: COMPANY OVERVIEW 328
TABLE 331 MESO SCALE DIAGNOSTICS LLC: COMPANY OVERVIEW 329
TABLE 332 RANDOX LABORATORIES LTD.: COMPANY OVERVIEW 330
TABLE 333 AMPRION DIAGNOSTICS: COMPANY OVERVIEW 331
TABLE 334 ATILA BIOSYSTEMS: COMPANY OVERVIEW 332
TABLE 335 QUANTERIX: COMPANY OVERVIEW 333
TABLE 336 ALAMAR BIOSCIENCES: COMPANY OVERVIEW 334
TABLE 337 GENEPROOF: COMPANY OVERVIEW 335
TABLE 338 BODY FLUID ANALYSIS MARKET: RISK ASSESSMENT 347
FIGURE 1 BODY FLUID ANALYSIS MARKET SEGMENTATION 31
FIGURE 2 KEY INSIGHTS AND MARKET HIGHLIGHTS 35
FIGURE 3 GLOBAL BODY FLUID ANALYSIS MARKET, 2024–2031 35
FIGURE 4 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN BODY FLUID ANALYSIS MARKET, 2023–2025 36
FIGURE 5 DISRUPTIVE TRENDS IMPACTING GROWTH OF BODY FLUID ANALYSIS 37
FIGURE 6 HIGH-GROWTH SEGMENTS AND EMERGING FRONTIERS IN BODY FLUID ANALYSIS MARKET, 2025 38
FIGURE 7 ASIA PACIFIC TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD 39
FIGURE 8 RISING CASES OF CHRONIC DISEASES TO DRIVE MARKET 40
FIGURE 9 CONSUMABLES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 40
FIGURE 10 CLINICAL CHEMISTRY SEGMENT TO LEAD MARKET DURING FORECAST PERIOD 41
FIGURE 11 DIAGNOSTIC PRODUCTS SEGMENT TO LEAD MARKET DURING FORECAST PERIOD 41
FIGURE 12 CEREBROSPINAL FLUID TO LEAD MARKET DURING FORECAST PERIOD 42
FIGURE 13 CLINICAL DIAGNOSTICS SEGMENT TO LEAD MARKET DURING FORECAST PERIOD 42
FIGURE 14 HOSPITAL LABORATORIES SEGMENT TO LEAD MARKET DURING FORECAST PERIOD 43
FIGURE 15 ASIA PACIFIC TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD 43
FIGURE 16 BODY FLUID ANALYSIS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES,
AND CHALLENGES 44
FIGURE 17 BODY FLUID ANALYSIS MARKET: PORTER’S FIVE FORCES ANALYSIS 57
FIGURE 18 BODY FLUID ANALYSIS